疫苗合约製造市场 - 疫苗类型（减毒、灭活）、营运规模（商业、临床）、服务（灌装、散装）、产品类型（组合、单一）、应用、最终用户、全球预测（2024 年 -第2032章

Vaccine Contract Manufacturing Market - Vaccine Type (Attenuated, Inactivated), Scale of Operation (Commercial, Clinical), Service (Fill-finish, Bulk), Product Type (Combination, Single), Application, End-user, Global Forecast (2024 - 2032)

出版日期: 2024年06月03日 | 出版商:

Global Market Insights Inc. | 英文 220 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在外包趋势不断上升的推动下，全球疫苗合约製造市场 2024 年至 2032 年间的复合年增长率将达到 11%。製药公司越来越多地外包疫苗生产，以降低成本并专注于核心活动。随着製药公司越来越注重核心竞争力并寻求成本效率，他们转向专业的合约製造商来处理疫苗生产。外包使公司能够利用先进的技术和专业知识，而无需投资昂贵的基础设施。这一趋势是由新疫苗对可扩展性、灵活性和加快上市时间的需求所推动的。

例如，2024 年 5 月，全球领先的製药公司赛诺菲宣布一项超过 10 亿欧元（10.8 亿美元）的重大投资，以扩大法国三个基地的生物产能。这项投资是更广泛的 35 亿欧元计画的一部分，旨在减少法国和欧盟对外部製造来源的依赖。该倡议旨在增强供应链的安全性和弹性，并与欧盟的健康主权理念保持一致。这一概念在 COVID-19 大流行后受到重视，重点是加强製药系统、疫苗和医疗产品的製造能力，以及改善威胁侦测和回应机制。

此外，合约製造商提供监管合规性和品质保证，进一步增强了它们在不断扩大的疫苗市场中的吸引力。

整个疫苗合约製造业根据疫苗类型、营运规模、服务、产品类型、应用、最终用户和地区进行分类。

由于对针对各种传染病的可靠且安全的疫苗的需求，灭活疫苗合约製造市场将在 2024 年至 2032 年期间实现可观的增长。灭活疫苗利用灭活的病原体来刺激免疫反应，对于预防减毒活疫苗不适合的疾病至关重要。生产技术的进步，加上全球健康问题和疫情的日益严重，推动了对专业製造的需求。此外，对高品质、一致的疫苗生产的监管要求进一步增加了对灭活疫苗合约服务的需求。

到 2032 年，临床细分市场将占据相当大的市场份额。随着临床试验的进展，製药公司需要专门的生产设施来大量生产疫苗进行测试和评估。合约製造商提供必要的专业知识、技术和灵活性来处理不同规模的生产，同时确保遵守监管标准。此外，外包这些营运有助于简化开发时间表并降低成本，从而提高整体专案效率。

由于严格的监管标准需要专业化的生产能力，欧洲疫苗合约製造市场将在 2024 年至 2032 年大幅成长。对生物製药基础设施的投资增加和製造技术的进步也发挥了作用。欧洲专注于减少对非欧盟生产的依赖并增强供应链的弹性，特别是在疫情后，这推动了需求。此外，不断增长的公共和私营部门合作以及对可扩展生产解决方案的需求，进一步推动了该地区的合约製造市场。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 12 章：公司简介

Ajinomoto Co., Inc.
Bavarian Nordic A/S
Catalent, Inc
Charles River Laboratories International Inc.
Curia Global, Inc.
Cytovance Biologics (Hepalink)
Emergent BioSolutions Inc.
Fujifilm Holdings Corporation
Goodwin Biotechnology Inc.
Gedeon Richter (Richter-Helm BioLogics)
ICON PLC
IDT Biologika GmbH
Lonza Group AG
Recipharm AB
Syngene International Limited

简介目录

Product Code: 9726

Global Vaccine Contract Manufacturing Market will depict 11% CAGR between 2024 and 2032, driven by the rising outsourcing trends. Pharmaceutical companies increasingly outsource vaccine production to reduce costs and focus on core activities. As pharmaceutical companies increasingly focus on core competencies and seek cost efficiencies, they turn to specialized contract manufacturers to handle vaccine production. Outsourcing allows companies to leverage advanced technologies and expertise without investing in costly infrastructure. This trend is driven by the need for scalability, flexibility, and accelerated time-to-market for new vaccines.

For instance, in May 2024, Sanofi, a leading global pharmaceutical company, announced a major investment exceeding €1 billion ($1.08 billion) to expand bioproduction capacity at three sites in France. This investment is part of a broader €3.5 billion program aimed at reducing France's and the EU's reliance on external manufacturing sources. The initiative seeks to enhance supply chain security and resilience, aligning with the EU's health sovereignty concept. This concept, which gained prominence after the COVID-19 pandemic, focuses on strengthening pharmaceutical systems, manufacturing capacities for vaccines and medical products, and improving threat detection and response mechanisms.

In addition, contract manufacturers offer regulatory compliance and quality assurance, further boosting their appeal in the expanding vaccine market.

The overall vaccine contract manufacturing industry is categorized based on vaccine type, scale of operation, service, product type, application, end-user, and region.

The inactivated vaccine contract manufacturing market will drive commendable gains over 2024-2032, propelled by the need for reliable and safe vaccines against various infectious diseases. Inactivated vaccines, which use killed pathogens to stimulate immune responses, are crucial for preventing diseases where live attenuated vaccines are not suitable. Advances in production technology, coupled with rising global health concerns and outbreaks, drive the need for specialized manufacturing. Additionally, regulatory requirements for high-quality, consistent vaccine production further boost the demand for inactivated vaccine contract services.

The clinical segment will capture a substantial market share by 2032. The demand for vaccine contract manufacturing at a clinical scale is stimulated by the need for efficient and scalable production during vaccine development. As clinical trials progress, pharmaceutical companies require specialized manufacturing facilities to produce vaccines in large quantities for testing and evaluation. Contract manufacturers offer the necessary expertise, technology, and flexibility to handle varying scales of production while ensuring compliance with regulatory standards. Additionally, outsourcing these operations helps streamline development timelines and reduces costs, enhancing overall project efficiency.

Europe vaccine contract manufacturing market will grow substantially over 2024-2032 due to stringent regulatory standards that necessitate specialized production capabilities. Increased investment in biopharmaceutical infrastructure and advancements in manufacturing technologies also play a role. Europe's focus on reducing dependence on non-EU production and enhancing supply chain resilience, particularly post-pandemic, drives demand. Additionally, growing public and private sector collaborations, alongside the need for scalable production solutions, further boost the region's contract manufacturing market.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising demand for vaccines
  - 3.2.1.2 Increasing adoption of outsourcing services
  - 3.2.1.3 Technological advancements in vaccine technologies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory requirements
  - 3.2.2.2 Increasing cost of vaccines
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Attenuated
5.3 Inactivated
5.4 Subunit-based
5.5 Toxoid-based
5.6 DNA-based

Chapter 6 Market Estimates and Forecast, By Scale of Operation, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Commercial
6.3 Clinical
6.4 Preclinical

Chapter 7 Market Estimates and Forecast, By Service, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Fill-finish
7.3 Bulk vaccines

Chapter 8 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Combination vaccine
8.3 Single vaccine

Chapter 9 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Human
9.3 Veterinary

Chapter 10 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 Pharmaceutical & biotechnology companies
10.3 Academic and research institutes

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

11.1 Key trends
11.2 North America
- 11.2.1 U.S.
- 11.2.2 Canada
11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 France
- 11.3.4 Spain
- 11.3.5 Italy
- 11.3.6 Netherlands
- 11.3.7 Rest of Europe
11.4 Asia Pacific
- 11.4.1 China
- 11.4.2 Japan
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 South Korea
- 11.4.6 Rest of Asia Pacific
11.5 Latin America
- 11.5.1 Brazil
- 11.5.2 Mexico
- 11.5.3 Rest of Latin America
11.6 Middle East and Africa
- 11.6.1 South Africa
- 11.6.2 Saudi Arabia
- 11.6.3 UAE
- 11.6.4 Rest of Middle East and Africa